Setidegrasib
Highest phase reached
Phase 2
Drug type
Small molecule
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Small molecule
- Drug name
- Setidegrasib
- Structure (SMILES)
- c1n[nH]c2cc(c(C)c(c21)-c3c(OCc4ccc(cc4)-c5cn([C@H](C(=O)N6C[C@@H](C[C@H]6C(N[C@H](c7ccc(-c8c(ncs8)C)cc7)CO)=O)O)C(C)C)nn5)c9c(c(N%10[C@@]%11(CN[C@@]([H])(C%11)C%10)[H])nc(n9)OC%12CCOCC%12)cc3C%13CC%13)F
- 2 pyrrolidinecarboxamide 1 2s 2 4 4 6 cyclopropyl 4 1s 4s 2 5 diazabicyclo 2 2 1 hept 2 yl 7 6 fluoro 5 methyl 1h indazol 4 yl 2 tetrahydro 2h pyran 4 yl oxy 8 quinazolinyl oxy methyl phenyl 1h 1 2 3 triazol 1 yl 3 methyl 1 oxobutyl 4 hydroxy n 1r 2 hydroxy 1 4 4 methyl 5 thiazolyl phenyl ethyl 2s 4r
- 2-Pyrrolidinecarboxamide, 1-[(2S)-2-[4-[4-[[[6-cyclopropyl-4-(1S,4S)-2,5-diazabicyclo[2.2.1]hept-2-yl-7-(6-fluoro-5-methyl-1H-indazol-4-yl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]-8-quinazolinyl]oxy]methyl]phenyl]-1H-1,2,3-triazol-1-yl]-3-methyl-1-oxobutyl]-4-hydroxy-N-[(1R)-2-hydroxy-1-[4-(4-methyl-5-thiazolyl)phenyl]ethyl]-, (2S,4R)-
- setidegrasib
- Setidegrasib
- setidegrasib [INN]
- Setidegrasib [WHO-DD]
- setidegrasib inn
- setidegrasib who dd
- CAS registry numbers
- 2821793-99-9
- ChEMBL ID
- CHEMBL6068173
- InChIKey
- XXWMEQMGQNHRAF-WFJRNIGCSA-N
- PubChem compound IDs
- 164875418
- FDA ingredient codes (UNII)
- 3NQ4ME292X
- First in class
- No
- Orphan designation
- No
- Drug name stem
- -rasib
Investigated indications
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition identifier
- EFO_0000616
- Condition identifier
- MONDO_0005070
- Condition identifier
- MONDO_0005184
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005233
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0006047
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0009831
- Highest recorded phase
- 3
- Calculated partition coefficient (XLogP)
- 7.7
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Heavy atoms
- 81
- Monoisotopic mass
- 1116.48039179
- Natural product
- No
Related records
Trials (4)
- A Study of ASP3082 in Adults With Advanced Solid Tumors
- A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation
- A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults
In development for (1)
- Neoplasm Phase 2